VIRC:NASDAQVirco Manufacturing Corporation Analysis
Data as of 2026-05-09 - not real-time
$6.06
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Virco’s stock is trading at $6.06, which sits below its 20‑day (6.09) and 50‑day (6.12) moving averages and well under the 200‑day level of $6.93, confirming a bearish technical backdrop. The RSI of 48.9 places the security near the neutral zone, while the MACD histogram is marginally positive, indicating a tentative bullish signal that has not yet overcome the prevailing downtrend. Volume has been shrinking, and the 30‑day volatility of 33% together with a historic max drawdown of nearly 40% underline a high‑risk price environment. Support is identified around $5.42 and resistance near $6.45, suggesting limited upside in the near term unless a catalyst intervenes.
Fundamentally, the company posted a modest net income of $2.6 million on $199.7 million revenue, yielding a profit margin of just 1.3% and an operating margin that remains negative, while operating cash flow and free cash flow are both negative. However, the forward earnings estimate jumps to $1.76 per share, compressing the forward P/E to about 3.4 versus a trailing P/E of 37.9, which signals a potentially large earnings upside. Insider activity has been supportive, with the CEO and other executives buying roughly $100 k of shares over the past month at prices ranging from $5.52 to $6.22. The dividend yield of 1.64% is paid out at a 62% payout ratio, but the negative cash flows raise questions about its sustainability. Overall, the market’s “Extreme Greed” sentiment (Fear‑Greed Index 90.7) and analyst target price of $7 imply about a 15% upside from current levels.
Fundamentally, the company posted a modest net income of $2.6 million on $199.7 million revenue, yielding a profit margin of just 1.3% and an operating margin that remains negative, while operating cash flow and free cash flow are both negative. However, the forward earnings estimate jumps to $1.76 per share, compressing the forward P/E to about 3.4 versus a trailing P/E of 37.9, which signals a potentially large earnings upside. Insider activity has been supportive, with the CEO and other executives buying roughly $100 k of shares over the past month at prices ranging from $5.52 to $6.22. The dividend yield of 1.64% is paid out at a 62% payout ratio, but the negative cash flows raise questions about its sustainability. Overall, the market’s “Extreme Greed” sentiment (Fear‑Greed Index 90.7) and analyst target price of $7 imply about a 15% upside from current levels.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages
- Decreasing volume and high recent volatility
- Support level near $5.42 limiting downside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward P/E of ~3.4 indicating strong earnings upside
- Insider buying signaling confidence
- Target price of $7 suggesting ~15% upside
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Persistent negative cash flow and high debt‑to‑equity
- Modest dividend yield with sustainability concerns
- Cyclical consumer sector exposure
Key Metrics & Analysis
Financial Health
Revenue Growth-8.00%
Profit Margin1.29%
P/E Ratio37.9
ROE2.39%
ROA1.20%
Debt/Equity38.11
P/B Ratio0.9
Op. Cash Flow$-841000
Free Cash Flow$-13459000
Technical Analysis
TrendBearish
RSI48.9
Support$5.42
Resistance$6.45
MA 20$6.09
MA 50$6.12
MA 200$6.93
MACDBullish
VolumeDecreasing
Fear & Greed Index90.73
Valuation
Target Price$7.00
Upside/Downside15.51%
GradeUndervalued
TypeBlend
Dividend Yield1.64%
Risk Assessment
Beta0.81
Volatility33.25%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.